Karyopharm director Mikael Dolsten resigns; Peter Honig elected to board

Karyopharm Therapeutics Inc.

Director Mikael Dolsten resigned effective Dec 2, 2021, citing competing professional demands, no disagreement.
Peter Honig elected independent director effective Dec 3, 2021, filling a vacancy, Class III term until 2022 annual meeting.
Honig appointed to Commercialization and Portfolio Committee; awarded option for 47,800 shares at $6.72, vesting over 3 years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mikael Dolsten

Director

KPTI · Karyopharm Therapeutics Inc.

Effective: 2021-12-02
Filed: December 6, 2021, 6:59 PM ET

On December 2, 2021, Mikael Dolsten, MD, PhD, notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors (the “Board”), effective immediately.

Appointed

Peter Honig

Director

KPTI · Karyopharm Therapeutics Inc.

Effective: 2021-12-03
Filed: December 6, 2021, 6:59 PM ET

On December 3, 2021, the Board, upon the recommendation of the Nominating, Corporate Governance & Compliance Committee of the Board, elected Peter K Honig, M.D., MPH, as an independent director of the Company to fill a vacancy on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mikael Dolsten resigned as Director at Karyopharm Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

On December 2, 2021, Mikael Dolsten, MD, PhD, notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors (the “Board”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Honig was elected as Director at Karyopharm Therapeutics Inc..

Action: elected
Role: Director

Exact text from the filing

On December 3, 2021, the Board, upon the recommendation of the Nominating, Corporate Governance & Compliance Committee of the Board, elected Peter K Honig, M.D., MPH, as an independent director of the Company to fill a vacancy on the Board.

View on SEC.gov

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-349022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.